PODCAST · health
OT Broadcast News
by Oncology Times
Audio-reports and interviews done in collaboration with Audio Medica and its founding Editor Peter Goodwin. Audio Medica's Audio Journal of Oncology has been bringing lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.
Episodes
-
Straight Talk with Dr. Brian J. Bolwell: Values
Welcome to the Oncology Times Podcast. Today on the Pod - Why do relatively few leaders live good values consistently? Why are so many people, especially in academic medicine, consumed with values that are emotion-based? We will discuss these ideas and more with Dr. Brian J. Bolwell, the Chairman...
-
Straight Talk with Dr. Brian J. Bolwell: Moments
In his recurring Oncology Times column "Straight Talk: Today's Cancer Centers," Brian J. Bolwell, MD dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell revisits his column "Moments," and discusses how to foster vulnerability, create psychological safety on a team, and...
-
Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'
Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.
-
From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)
Speaking at the meeting in Barcelona, Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions after immunochemotherapy had only half the risk of recurrence if they also received rituximab maintenance therapy for two years compared with...
-
OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS
Dr. Sekeres, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute and Chair of the Hematology/Oncology Pharmacy & Therapeutics Committee, discusses his particular research interests of myelodysplastic syndromes and acute myelogenous leukemia, including the overlaps...
-
OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD
Dr. Govindan, Professor of Medicine and Director of the Thoracic Medical Oncology Program at Washington University Alvin J. Siteman Cancer Center, elaborates on his article in the April 10 issue about the promise and excitement of the new advances in technology that are now making possible a...
-
Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference
Lori Pierce on breast-conserving therapy + adjuvant chemotherapy for BRCA 1 & 2 carriers; Annette Heemskerk-Gerritsen on the relationship between contralateral mastectomy & survival; and a recommendation by Ajay Sahu for a "cooling off" period for low-risk patients thinking of having prophylactic...
-
Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference
Oncology Times Hatem Azim on how pregnancy after breast cancer is safe and possibly protective; Angela Ives on why recent -- but not current -- pregnancy worsens breast cancer prognosis; and Sibylle Loibl on how chemotherapy is not generally hazardous to the fetus. Martine Piccart adds commentary…
more -
Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome
John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.
-
The Disappointment of the NSABP C-08 Trial
Norman Wolmark on the study's frustrating but unequivocal results showing that bevacizumab did not extend disease-free survival in adjuvant therapy for early colon cancer at 3 years, even though there had been a benefit at 1 year. Also weighing in: Nicholas Petrelli
-
Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue!
Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at...
-
Research Policy Expert: Overhaul Cancer Research Priorities Globally Now!
Richard Sullivan at ECCO15-ESMO34 on the need for research that is more “trans-national” and funded globally to shift priorities to prevention, surgical innovation and technological development, and creative, “outward branching” thinking. The need, he says, is not just for more investment but for…
more -
Swedish Registry Study Shows Hormone Therapy for Prostate Cancer Increased All Cardiovascular Mortality
Mieke Van Hemelrijck at ECCO15-ESMO34 on findings that cardiovascular mortality from heart failure and arrhythmia in addition to ischemic heart disease and myocardial infarction increased among patients treated with endocrine therapy—of whatever type—for their prostate cancer.
-
Advanced Biliary Cancer Controlled with Cetuximab Added to GEMOX
Éveline Boucher of Centre Eugene Marquis in France on the encouraging preliminary results of her Phase II open-label study of 101 patients reported at the ESMO World Congress on Gastrointestinal Cancer
-
Metastatic Colorectal Cancer: Capecitabine Equivalent to 5-FU in Irinotecan/Bevacizumab Combos
Michel Ducreux, Head of the GI Service at Institut Gustave Roussy, talks about the new evidence and its clinical implications, as reported in his Phase II study at the ESMO World Congress on Gastrointestinal Cancer.
-
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Doubles Progression-Free Survival in Phase III Study
Eric Raymond of Beaujon University Hospital in France discusses his study reported at the ESMO World Congress on Gastrointestinal Cancer
-
KRAS-Driven Selection of Molecular Therapy for Metastatic Colorectal Cancer: Choosing Between Bevacizumab, Cetuximab, Panitumomab, or a Combination
Interviewed at the Palm Beach Cancer Symposium, John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles, talks about his latest data on the relevance of KRAS tumor status—i.e., whether the gene is wild-type or mutant determines the sensitivity of the tumor to anti-EGF or anti-VEGF...
-
CML: Hagop Kantarjian on Treating Patients with the T315I Mutation
Also: (1) Feasibility of patients becoming pregnant while having TKI treatment after having stable disease for at least two years; and (2) Decreased need for allogeneic transplant.
-
Oropharyngeal Cancer: Better Outlook with HPV-Directed Therapies
Marshall Posner, MD, talking from Palm Beach Cancer Symposium: Increased prevalence of HPV-related oropharyngeal cancers, more responsive to treatment with induction docetaxel, cisplatin, & 5-FU prior to standard chemoradiotherapy.
-
Breast Cancer: St. Gallen Meeting Endorses Multi-Gene Assays for Refining Chemo Decision
Also from the Palm Beach Cancer Symposium, Kathy Albain, MD, talks about the St. Gallen consensus meeting’s updated recommendations about adjuvant therapy for breast cancer—i.e., endorsing the 21-gene recurrence score and 70-gene profiling assay as key tools in decision-making for chemotherapy…
more -
The Smartest Oncologist in the World? – Well, at least in the US!
Stanley H. Winokur, MD, on his clever, fun, and ever-evolving one-minute daily Internet quiz that lets oncologists test their knowledge & compete against others. TheSmartestOncologist.com
-
Cancer-Related Fatigue
Paddy Stone of St. George's Hospital, University of London, & David Cella from Northwestern University Feinberg School of Medicine about the effective use of questionnaires for assessing, screening, and perhaps diagnosing cancer-related fatigue syndrome.
-
Bilateral Prophylactic Mastectomy for DCIS
Todd Tuttle from University of Minnesota & Abram Recht from Beth Israel Deaconess Medical Center on the surprisingly big recent increase in the use of prophylactic bilateral mastectomy for DCIS.
-
10th European Congress on Perspectives in Lung Cancer, Brussels
Silvia Novello and Giorgio Scagliotti on harnessing insulin-like growth factor receptor inhibition in a Phase II study that showed clinical activity of figitumumab to be at least as good as that of inhibitors of other growth factors already being used in cancer.
-
More from the ASH Annual Meeting!
Greater Role for Umbilical Cord Blood in Adult Transplants (Mary Eapen, commentary from Armand Keating). Ex Vivo Expansion of Cord Blood Derived Progenitor Cells: Patient Transplant Data (Colleen Delaney, commentary from Armand Keating). Erythropoiesis-Stimulating Agents in Cancer Patients:...
-
ASH Annual Meeting
Peter Goodwin talks to key investigators Francesco Zaja (on rituximab for ITP); Hannes Wandt (on how platelet transfusions may be able to be withheld in certain patients receiving stem cell transplants for hematologic cancers); and Michael Hallek and Tadeusz Robak (on improved benefits for CLL...
-
NCRI Conference, ASCO Annual Meeting, and Perspectives in Lung Cancer European Congress
New research for advanced NSCLC showing that combining monoclonal antibodies and chemotherapy can extend life: OTBN Editor Peter Goodwin and Producer Sarah Maxwell talk to Robert Pirker, Christian Manegold, Giorgio Scagliotti, Nick Thatcher, and Howard Sandler, MD. PLUS: Michel Coleman on the...
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Audio-reports and interviews done in collaboration with Audio Medica and its founding Editor Peter Goodwin. Audio Medica's Audio Journal of Oncology has been bringing lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVie, MD, of the European Institute of Oncology and Chair of the Editorial Board of OT's UK Edition; Pat Price, MD, of Christie Hospital, also on the OTUK Editorial Board; and Gianni Bonadonna, MD, of Istituto Nazionale Tumori.
HOSTED BY
Oncology Times
Loading similar podcasts...
Frequently Asked Questions
How many episodes does OT Broadcast News have?
OT Broadcast News currently has 28 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is OT Broadcast News about?
Audio-reports and interviews done in collaboration with Audio Medica and its founding Editor Peter Goodwin. Audio Medica's Audio Journal of Oncology has been bringing lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are George...
How often does OT Broadcast News release new episodes?
OT Broadcast News has 28 episodes. Check the episode list to see recent publication dates and frequency.
Where can I listen to OT Broadcast News?
You can listen to OT Broadcast News on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts OT Broadcast News?
OT Broadcast News is created and hosted by Oncology Times.
URL copied to clipboard!